| Literature DB >> 31847847 |
Mohamed Sunil1, Huynh Quoc Hieu2, Ramesh Singh Arjan Singh1, Sasheela Ponnampalavanar1, Kelvin S W Siew1, Alexander Loch3.
Abstract
BACKGROUND: Staphylococcus has replaced streptococcus as the most common cause of infective endocarditis (IE) in developed health care systems. The trend in developing countries is less clear. AIM: To examine the epidemiological trends of infective endocarditis in a developing nation.Entities:
Keywords: Healthcare associated infection; Infective endocarditis; Malaysia; Mortality predictors; Staphylococcus aureus
Mesh:
Substances:
Year: 2019 PMID: 31847847 PMCID: PMC6918620 DOI: 10.1186/s12941-019-0341-x
Source DB: PubMed Journal: Ann Clin Microbiol Antimicrob ISSN: 1476-0711 Impact factor: 3.944
Fig. 1Patient recruitment
Fig. 2Infective Endocarditis incidence per year
Microbial agents and resistance pattern of culture positive cases (n = 142)
| Organism | n | % | Sensitive to | |
|---|---|---|---|---|
| Methicillin | Vancomycin | |||
| 58 | 40.8 | |||
| | 48 | 33.8 | ||
| | 44 | 31.0 | 44 | – |
| | 4 | 2.8 | 0 | 4 |
| MRCoNS | 10 | 7.0 | 0 | 10 |
MRCoNS methicillin-resistant coagulase-negative staphylococcus, NOS not otherwise specified, MSSA methicillin-sensitive Staphylococcus aureus, MRSA methicillin-resistant Staphylococcus aureus, NA not applicable
Major IE studies
| This study | Ibrahim et al. [ | Gupta et al. [ | Xu et al. [ | Poesen et al. [ | Watt et al. [ | Toyoda et al. [ | |
|---|---|---|---|---|---|---|---|
| Time of study | 2005–2017 | 2012–2013 | 2005–2010 | 2008–2015 | 2003–2010 | 2010–2012 | 1998–2013 |
| Country | Malaysia | Malaysia | India | China | Belgium | Thailand | US |
| Episodes | 182 | 50 | 61 | 174 | 88 | 132 | 75,829 |
| Incidence (per 100,000 adm) | 31 | NA | 80 | NA | 54 | NA | 7.6–9.3 |
| Age (years) (SD/IQR) | 51 ± 17.62 | 42 ± 16.4 | 49 ± 13.7 | 48 ± 15.7 | 72 IQR 59–81 | 47 IQR 16–85 | 62 ± 18.9 |
| Male: female ratio | 2.4:1 | 2.8:1 | 3.3:1 | 1.9:1 | 2:1 | 2.2:1 | 1.4:1 |
| Predispositions (%) | |||||||
| RHD | 42 | NA | 37.7 | 14.9 | 2.3 | 28.0 | NA |
| CHD | 7.7 | 6.0 | 22.9 | 29.9 | 5.7 | 8.3 | 4.5 |
| Dialysis | 9.3 | 6.0 | NA | 3.4 | 4.5 | NA | 18.4 |
| IVDU | 4.9 | 26.0 | 1.6 | 0.6 | 1.1 | NA | 12.5 |
| HIV | 2.7 | 4.0 | NA | NA | NA | NA | 1.7 |
| Culture positive (%) | 78 | 68 | 67.2 | 60.3 | 89.8 | 45.5 | 73.0 |
| HCAIE (%) | 37.4 | NA | NA | NA | NA | NA | 52.9 |
| PVE (%) | 6 | NA | 31 | 5.2 | 8 | 9.9 | 12.9 |
| Organisms (%) | |||||||
| Streptococcus | 35.9 | 20 | 21.4 | 37.4 | 44.4 | 22 | 26.6 |
| Staphylococcus | 40.8 | 36 | 21.4 | 13.8 | 21.7 | 5.3 | 38.5 |
| Complications (%) | |||||||
| CHF | 28.6 | NA | 47.5 | 69.0 | 51.1 | 48 | NA |
| Stroke | 19.2 | 10.0 | 11.5 | 16.1 | NA | NA | NA |
| Surgery for IE (%) | 32 | 20.0 | 49.2 | 43.7 | 29.5 | 75.8 | NA |
| In-hospital death (%) | 36.7 | 28.0 | 6.6 | 10.9 | 17.0 | 11.4 | 24.0a |
SD standard deviation, IQR interquartile range, RHD rheumatic heart disease, CHD congenital heart disease, IVDU intravenous drug use, HCAIE health care associated IE, PVE prosthetic valve IE, CHF congestive heart failure, IE infective endocarditis, NA not available
a90 days mortality in this study